Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zbigniew Nowecki

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Clinical Chemistry|August 21, 2003
Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanomaJolanta Szenajch, Bogdan Jasiński, Agnieszka Synowiec, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC StudyAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
International Journal of Molecular Sciences|May 14, 2025
Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-AlphaAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
Nature Cancer|June 8, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trialPeter Schmid, Seock-Ah Im, Zbigniew Nowecki, et al.
Cardio-Oncology (London, England)|September 28, 2024
Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicityAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
International Journal of Cancer|June 9, 2004
Increased cancer risk of heterozygotes with NBS1 germline mutations in PolandJan Steffen, Raymonda Varon, Maria Mosor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerXavier Pivot, Igor Bondarenko, Zbigniew Nowecki, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Breast Cancer (Dove Medical Press)|December 30, 2025
Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent TherapiesKatarzyna Pogoda, Hubert Pawlik, Anna Balata, et al.
Breast Cancer Research and Treatment|March 22, 2021
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Carlo A Tondini, Jacinta Abraham, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Clinical Chemistry|August 21, 2003
Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanomaJolanta Szenajch, Bogdan Jasiński, Agnieszka Synowiec, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC StudyAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
International Journal of Molecular Sciences|May 14, 2025
Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-AlphaAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
Nature Cancer|June 8, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trialPeter Schmid, Seock-Ah Im, Zbigniew Nowecki, et al.
Cardio-Oncology (London, England)|September 28, 2024
Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicityAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
International Journal of Cancer|June 9, 2004
Increased cancer risk of heterozygotes with NBS1 germline mutations in PolandJan Steffen, Raymonda Varon, Maria Mosor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerXavier Pivot, Igor Bondarenko, Zbigniew Nowecki, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Breast Cancer (Dove Medical Press)|December 30, 2025
Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent TherapiesKatarzyna Pogoda, Hubert Pawlik, Anna Balata, et al.
Breast Cancer Research and Treatment|March 22, 2021
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Carlo A Tondini, Jacinta Abraham, et al.
Pageof 4